Publications (43) View all
-
Article: Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose.
Rianne Mf van Schie, Judith Am Wessels, Talitha I Verhoef, Tom Schalekamp, Saskia le Cessie, Felix Jm van der Meer, Frits R Rosendaal, Loes E Visser, Martina Teichert, Albert Hofman, Peter Nm Buhre, Anthonius de Boer, Anke-Hilse Maitland-van der Zee[show abstract] [hide abstract]
ABSTRACT: Aim: To investigate whether the phenprocoumon and acenocoumarol maintenance doses are influenced by genetic variations in GATA-4, a transcription factor of CYP2C9. Patients & methods: The influence of seven GATA-4 SNPs on the coumarin maintenance dose was investigated by performing an analysis of variance trend analysis, stratified for CYP2C9 genotypes. Results of the best-explaining SNP were validated in the Rotterdam Study cohort. Results: The largest dose differences were found for rs3735814 in patients using acenocoumarol and having the common allele for CYP2C9. The mean dosages decreased from 2.92 mg/day for the patients having the GATA-4 common alleles to 2.65 mg/day for the patients carrying one GATA-4 variant allele and to 2.37 mg/day for patients carrying two GATA-4 variant alleles (p = 0.004). Results could not be replicated in the validation cohort. For phenprocoumon, no significant effects were observed. Conclusion: Genetic variation in GATA-4 does not seem relevant for clinical implementation. Original submitted 31 August 2012; Revision submitted 12 October 2012.Pharmacogenomics 12/2012; 13(16):1917-1923. · 3.97 Impact Factor -
Article: Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose.
Rianne M F van Schie, Talitha I Verhoef, Saskia B Boejharat, Tom Schalekamp, Judith A M Wessels, Saskia le Cessie, Frits R Rosendaal, Felix J M van der Meer, Anthonius de Boer, Anke-Hilse Maitland-van der Zee[show abstract] [hide abstract]
ABSTRACT: Abstract Background: Statins and coumarins are prescribed in combination on a regular basis. Some case reports suggested that statins might affect the dose requirements of coumarins. The aim of the study was to investigate whether acenocoumarol and phenprocoumon maintenance doses are influenced by statin use. Methods: The Pre-EU-PACT database was used, which contains information on 471 acenocoumarol and 624 phenprocoumon users. The influence of individual statins on the acenocoumarol and phenprocoumon maintenance dose was investigated by comparing unadjusted and adjusted mean differences of the maintenance dose between statin and non-statin users. Results: Lower adjusted acenocoumarol dose requirements were observed for patients using atorvastatin, simvastatin, pravastatin, and rosuvastatin. These patients had a reduction in adjusted mean acenocoumarol maintenance dose of 0.11, 0.29, 0.38, and 0.69 mg/day, respectively, compared with a mean adjusted dose of 2.60 mg/day for the patients not using a statin. There was no significant effect of statin use on unadjusted and adjusted phenprocoumon maintenance dose (p=0.23 and p=0.35, respectively). Conclusions: Mean acenocoumarol maintenance dosages were decreased when acenocoumarol is co-administered with the different statins. Statin use does not affect phenprocoumon maintenance doses significantly.Drug metabolism and drug interactions 09/2012; -
Article: Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study.
Rianne M F van Schie, Nadia el Khedr, Talitha I Verhoef, Martina Teichert, Bruno H Stricker, Albert Hofman, Peter N Buhre, Judith A M Wessels, Tom Schalekamp, Saskia le Cessie, Felix J M van der Meer, Frits R Rosendaal, Anthonius de Boer, Anke-Hilse Maitland-van der Zee, Loes E Visser[show abstract] [hide abstract]
ABSTRACT: To evaluate the performance of the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) acenocoumarol dose algorithms in an independent data set. The EU-PACT trial investigates the added value of pretreatment genotyping for use of warfarin, phenprocoumon and acenocoumarol. External validation was performed in the Rotterdam Study cohort using information about 707 acenocoumarol users. R(2), which measures the strength of correlation between the predicted and observed acenocoumarol dose, mean absolute error and mean squared error were calculated to evaluate the performance of the original algorithm. Validation resulted in a R(2) of 52.7 and 12.9% compared with an R(2) of 52.6 and 17.8% in the original study for the genotype-guided and nongenotype-guided dose algorithm, respectively. For the genotype-guided dose algorithm, the mean absolute error was 0.48 mg/day and the mean squared error was 0.38 (mg/day)(2). For the nongenotype-guided dose algorithm, the mean absolute error was 0.62 mg/day and the mean squared error was 0.63 (mg/day)(2). The EU-PACT acenocoumarol algorithm performs just as accurately in this study as in the original study, which implies applicability in various populations.Pharmacogenomics 08/2012; 13(11):1239-45. · 3.97 Impact Factor -
SourceAvailable from: T.I. Verhoef
Chapter: Future of Pharmacogenetics in Cardiovascular Diseases
Rianne M.F. Van Schie, Talitha I. Verhoef, Anke-Hilse Maitland-Van Der Zee, Anthonius de Boer, Tom Schalekamp, Felix J.M. Van Der Meer, William K. Redekop, Rahber Thariani03/2012; , ISBN: 978-953-51-0222-9 -
Article: Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
Rianne M F van Schie, Judith A M Wessels, Saskia le Cessie, Anthonius de Boer, Tom Schalekamp, Felix J M van der Meer, Talitha I Verhoef, Erik van Meegen, Frits R Rosendaal, Anke-Hilse Maitland-van der Zee[show abstract] [hide abstract]
ABSTRACT: Polymorphisms in CYP2C9 and VKORC1 influence patients' phenprocoumon (PHE) and acenocoumarol (ACE) dose requirements. To provide physicians with tools to estimate the patient's individual dose, we aimed to develop algorithms for PHE and ACE. In two Dutch anticoagulation clinics, data on age, sex, height, weight, co-medication, coumarin derivative doses, and international normalized ratio values were obtained from 624 patients taking PHE and 471 taking ACE. Single nucleotide polymorphisms relevant to coumarin derivative dosing on the CYP2C9 and VKORC1 genes were determined. Using multiple linear regression, we developed genotype-guided and non-genotype-guided algorithms to predict the maintenance dose with patient characteristics and genetic information. In addition, loading doses were derived from the calculated maintenance doses. We performed external validation in an independent data set with 229 PHE and 168 ACE users. CYP2C9 and VKORC1 genotype, weight, height, sex, age, and amiodarone use contributed to the maintenance dose of PHE and ACE. The genotype-guided algorithms explained 55.9% (PHE) and 52.6% (ACE) of the variance of the maintenance dose, the non-genetic algorithms 17.3% (PHE) and 23.7% (ACE). Validation in an independent data set resulted in an explained variation of 59.4% (PHE) and 49.0% (ACE) for the genotype-guided algorithms and for 23.5% (PHE) and 17.8% (ACE) for the non-genotype-guided algorithms, without height and weight as parameters. To our knowledge, these are the first genotype-guided loading and maintenance dose algorithms for PHE and ACE using large cohorts. The utility of these algorithms will be tested in randomized controlled trials.European Heart Journal 06/2011; 32(15):1909-17. · 10.48 Impact Factor